<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The fungal MIC was performed using the biological strains aforementioned (
 <xref ref-type="sec" rid="sec2dot1dot2-pharmaceutics-10-00257" class="xref">Section 2.1.2</xref>). The inocula were diluted in Mueller–Hinton broth (MHB) at the ratio of 1:30 according to an adaptation from the method described by Oliveira et al. (2018) [
 <xref rid="B18-pharmaceutics-10-00257" ref-type="bibr" class="xref">18</xref>]. The BBE and the BME were diluted in sterile MHB and bullfrog oil was diluted with DMSO at 1% in sterile MHB in order to obtain an oil concentration of 4 mg·mL
 <sup class="sup">−1</sup> for all samples. The DMSO solution at 1% and the BME were used as negative control. Serial dilutions (emulsion: MHC, 1:2 
 <italic class="italic">v</italic>/
 <italic class="italic">v</italic>) were prepared with sterile MHC in a 96-well microplate and incubated at 37 °C ± 2 °C for 48 h. The fungal MIC was considered as the lowest concentration of the samples able to inhibit 100% growth of each strain by visual inspection, according to the recommended by the Clinical Laboratory Standards Institute [
 <xref rid="B27-pharmaceutics-10-00257" ref-type="bibr" class="xref">27</xref>].
</p>
